Category Archives: Biotechnology

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will hold its annual Biotechnology Conference on Monday, August 8th and Tuesday, August 9, 2022, in New York. The firm will host over 125 established and emerging healthcare company management teams for one-on-one investor meetings and thematic panel discussions with industry leaders. Panel themes will include biotech policy updates, KRAS targeting modalities, immuno-oncology, pulmonary medication development, cell therapy advancements, CNS AAV gene therapy developments, retinal disease developments, buyside biotech investor sentiment and more.

The conference will be hosted by:

Our biotechnology team has attracted some of the industrys most respected thought leaders and corporate management teams to participate in our upcoming conference, commented Ryan Serwin, CFA, Director of Research at BTIG. We look forward to producing this hybrid event, where we bring together key public and private biotechnology companies with institutional investors to explore emerging innovations and discuss impactful trends across the industry.

For more information about the conference, email info@btig.com. Please note that participants must be pre-registered to attend. To access BTIG insights, contact a firm representative or log in to http://www.btigresearch.com.

About BTIG

BTIG is a global financial services firm specializing in institutional trading, investment banking, research, and related brokerage services. With an extensive global footprint and more than 750 employees, BTIG, LLC and its affiliates operate out of 23 cities throughout the U.S., and in Europe, Asia, and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency, and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firms core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.

Disclaimer: https://www.btig.com/disclaimer. To learn more about BTIG, visit http://www.btig.com.

Read more here:
BTIG to Host Biotechnology Conference on August 8-9, 2022 - Business Wire

Officials at the University of Rwanda (UR) have said they are ready to roll out a masters degree in biotechnology, the field of study that could boost treatment of deadly diseases in the future.

This was highlighted in Kigali on Friday, August 12 at the end of weeklong deliberations about the implementation of the biotech programme, in which dozens of academics from Rwanda and foreign universities, policy makers, scientists and development partners took part.

The first cohort of candidates for the master's degree could begin their studies inearly 2023,The New Timeshas learnt.

Rwanda needs experts in biotechnology more than ever as the country embarks on developing its capacity invaccine manufacturingand genetic engineering, the officials said.

Locally trained scientists and biotech engineers could drive research in medical treatments, agriculture, foodprocessing and waste management, among other sectors.

The UR already has a bachelors programme in biotechnology. But it only offers basic skills, which are limited in terms of research and manufacturing, the officials said.

When it comes to manufacturing of vaccines or developing a nationwide industry in food processing, these are no longer fields which can be run by someone with a bachelor's degree, because they have just the foundational skills," Dr. Ignace Gatare, the Principal of UR's College of Science and Technology, toldThe New Times.

"So, with the current move to produce vaccines locally, and you have heard about the manufacturing of seeds which are resistant to climate change, it is necessary to train another highly skilled pool of professionals and that happens only at masters and PhD levels.

He added that the PhD programme would start once masters is deemed successful.

At least 834,000 (about Rwf880 million), as part of the European Unions7 million funding for capacity buildingin vaccines production in Rwanda, has been earmarked for the program to start operations.

The programme, which awaits the university senate approval, will enrol a cohort of 20-30 students, Gatare said, and could even start later this year, if everything goes according to plan.

Incorporated in three UR colleges, the programme will be hosted at the College of Science and Technology in Kigali.

According to the officials, parastatals, such as the Rwanda Biomedical Centre, Rwanda Food and Drugs Authority and Rwanda Agriculture and Animal Resources Board, will be some of the beneficiaries of the biotech programme.

Players in the Rwandan health sector have welcomed the initiative saying it would not only improve treatment of diseases but also boost research in emerging diseases.

In the 1990s, most of the diseases we treated were malaria, typhoid, meningitis and others, which are no longer prevalent, said Dr. Jean Nyirinkwaya, a long-time investor in the local health industry.

But today, there are other emerging diseases, affecting the heart, kidneys and which require better treatment or transplantation. Theres also need to carry out more research to understand why some of these diseases affect people in different categories. The masters programme in biotechnology comes at the right time.

[emailprotected]

See the original post here:
University of Rwanda to introduce master's programme in biotechnology - The New Times

New Jersey, United States This Red Biotechnology Market research works as the best evaluation tool to track the progress of the industry and keep an eye on the competitors growth strategies. It further helps to keep you ahead of your business competitors. This report depicts a few potential problems and gives solutions to them by doing comprehensive research on the market scenario. Valuable information is provided here about a particular market segment according to product type, application, region type, and end user. By referring to this comprehensive Red Biotechnology market analysis report, it becomes possible for organizations to monitor the efficiency of sales, determine the quality of services offered by competitors, estimate the competition level in the market and understand the communication channels followed by competitors in the market.

This Red Biotechnology Market research report covers career outlooks, regional marketplaces, and an overview of the expectations of a number of end-use sectors. With the help of relevant market data, key organizations are able to obtain a competitive benefit over the competitors in the market and attain the best results for business growth. Furthermore, this Red Biotechnology market analysis report emphasizes doing a comparison between several various geographical markets in key regions such as North America, Europe, Middle East, Africa, Latin America, and Asia Pacific. It aims at covering complex structures to classifications to an easy-to-follow overview of different business sectors.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=11405

Key Players Mentioned in the Red Biotechnology Market Research Report:

Amgen Inc., F. Hoffmann-La Roche, Gilead Sciences Inc., CSL, Pfizer Inc.

A massive amount of information presented in this Red Biotechnology Market report helps business players to make beneficial decisions. Some of the major key aspects covered in this market analysis are key performance indicators, customer acquisition, and manufacturers list. Performance results of the marketing plan are also covered in this market analysis report. This market study report enables to bring the improvements required in the business. It further talks about how COVID-19 caused huge trauma in several major sectors. Key marketing channels, market growth opportunities, core marketing strategy, and current scope of the business are some of the major factors discussed in this report. It further briefs on the current position of the market. It depicts the effect of metrics on market trends, revenue, and leads.

Red BiotechnologyMarket Segmentation:

Red Biotechnology Market, By Product Type

Gene Recombinant Drugs Human Vaccines Blood Products Diagnostics Reagents Personalized Medicines Others

Red Biotechnology Market, By Application

Drug Discovery Drug Protection Genetic Testing Pharmacogenomics Gene Therapy Others

Red Biotechnology Market, By End User

Biopharmaceutical Business Research Organizations CMOs and CROs Others

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=11405

For Prepare TOC Our Analyst deep Researched the Following Things:

Report Overview:It includes major players of the Red Biotechnology market covered in the research study, research scope, market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the Red Biotechnology market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the Red Biotechnology market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the Red Biotechnology market by application, it gives a study on the consumption in the Red Biotechnology market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the Red Biotechnology market are profiled in this section. The analysts have provided information about their recent developments in the Red Biotechnology market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the Red Biotechnology market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the Red Biotechnology market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the Red Biotechnology market.

Key Findings:This section gives a quick look at the important findings of the research study.

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/red-biotechnology-market/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Read more here:
Red Biotechnology Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 This Is Ardee - This Is Ardee

With links to the Church of Scientology, anti-vaccine glyphosate litigator Robert F. Kennedy, Jr., Organic Consumers Association, US Right to Know, and Environmental Working Group, this former Reuters reporter has spearheaded the effort by organic promoters to discredit GMOs, glyphosate, and other agri-technological tools positioned to feed a growing global population and address climate change. Heres her story and why she does it.

Corey Booker has a new-found campaign: Capitalizing on public concerns about the weedkiller glyphosate (also sold under a now-expired patent by Monsanto as Roundup), claimed by its critics to cause cancer. Last Tuesday (June 19), the New Jersey Senator, head of the Committee on Agriculture, Nutrition and Forestry, participated in a webinar highlighting its alleged dangers.

The event was organized by a group called Farmers Footprint, which promotes regenerative and organic agriculture. If you believe the host, this panel was crafted to put dialogue over consensus and allow for the nuance and present all the different perspectives on how glyphosate affects planetary health.

That would have been a constructive conversation to have. Thats the opposite of what happened. To say that the webcast was rigged would be an understatement. No farmers, soil expert or independent regulators were invited. No epidemiologists or toxicologists. Just activists, including someone who goes under the name Glyphosate Girl. And, of course, Booker. And in case you werent sure about where the host stood on the glyphosate controversy, if you scrolled down on the event page at the hosts site, there was this:

The glyphosate attack seminar traces to an article by Carey Gillam in the UK The Guardian earlier in July. The piece reported on the routine release of years-old Centers for Disease Control data, which Gillam claimed (although the figure is not cited in the CDC release) found that 80% of Americans had traces of glyphosate in their urine.

Gillams piece was quickly disseminated by the usual leftwing channels but also became a favorite of the far right, from the Gospel News Networkto The Epoch Times, which makes the case that the government is untrustworthy. Shes beloved by activists, particularly those reflexively critical of Big Agriculture and advocates of organic farming. She was drafted by Farmers Footprint to moderate and guide the webinar.

The event went as would be expected. Glyphosate is a hidden killer. The agricultural industry conspires to hide the facts. The US EPA and other global agencies that have determined the herbicides is safe as used are part of a global conspiracy.

Booker bit. Three days later, he released a statement co-signed by eight Democratic senators, urging the US Fish and Wildlife Service to sharply restrict the use of glyphosate and other long-approved pesticides on National Wildlife Refuges without even suggesting what safer alternatives could be substituted. (There arent any.)

The original report and the seminar were panned by independent scientists. Why? Isnt the presence of a weedkiller in the human body something to be concerned about?

On the surface yes, but the article doesnt really address that threat, which turns out to be minimal to non-existent. Scientists were particularly critical by such exaggerations as disturbing and tied to cancer claims that most independent scientists would reject as hyperbolic or outright incorrect.

As independent scientists Geoffrey Kabat and Kevin Folta wrote in separate articles on the GLP, the numbers as reported by the CDC underscore the relative safety of glyphosate not its possible harmfulness. Micro-traces at infinitesimally small levels in the parts per billion (equivalentto 1 drop of impurity in 500 barrels of water or 1 cent out of $10 million) are no cause for concern. The human body always has potentially harmful substances but at levels too low to be actually harmful. For example, human tissues and blood normally contain small amounts of various radioactive isotopes, which are harmless at the levels at which they occur. Any lab could identify thousands of purportedly toxic chemicals

Specifically, our kidneys are designed to eliminate potential toxins. The presence of micro-traces of any of thousands of toxins in our urine, including glyphosate, is a reassuring sign that our body is functioning properly. The level of glyphosate found in this study is detectablebut negligible and harmless, as regulatory agencies worldwide have determined.

While science was not on the agenda, the article and panel did provide a star turn for Gillam. In her current position, she partners with the Environmental Working Group, an organic-industry funded activist and litigation-focused organization in producing a blog called The New Lede. She refers to herself on her LinkdedIn page as a modern-day Rachel Carson for her groundbreaking work in exposing decades of corporate secrets and deceptive tactics by powerful pesticide companies, including the global giant Monsanto.

In fact, Gillam has had a rocky professional history. Scientists call her a one-woman science wrecking ball who misunderstands chemical risk and systematically exaggerates the dangers of a weedkiller that the global regulatory community has unanimously determined is safe as used, both to human health and the environment. Well have more on glyphosate, the article, Gillams history, and The New Lede as we go along.

If you are not familiar with the global conversation surrounding glyphosate, it has become a touchstone in the debate over the future of farming. The weedkillers proponentsupwards of 98% of the worlds farmers and every major independent regulatory or oversight agency in the world, (19 of them), subscribe to the science that the weedkiller is safeboth in the environment and as it shows up in micro-traces in food.

One UN sub-agency, the International Agency for Research on Cancer (IARC), singularly strayed from the consensus and issued a hazard analysis, which does not evaluate real-life exposure [all 19 of the other agencies did a risk analysis, which evaluates the actual likelihood of getting cancer under real-life conditions; for an explanation, read this]. It concluded that the weedkiller poses a theoretical hazard to everyday applicators who apply it over many years or decades but drew no conclusion as to its trace risks in food.

[View hyperlinked GLP infographic to review the findings by the global agencies].

Nineteen of the 20 independent agencies reviewed IARCs hazard data in 23 studies and found its findings incomplete and its research methods shoddy or inadequate. As Health Canada recently noted (2019) after reviewing claims that glyphosate causes health problems:

No pesticide regulatory authority in the world currently considers glyphosate to be a cancer risk to humans at the levels at which humans are currently exposed.

That hasnt stopped the debate over the weedkiller from percolating in the media and in legislative halls, pitting the global regulatory and science community against activist groups who target synthetic agricultural chemicals (many of which are safer with less consequences to the environment, flora and fauna then organic alternatives). Risk in chemicals is challenging for most people to assess, which is why extremist activists like EWG and Gillam view targeting pesticides as the public-relations Achilles heel of mainstream agriculture as they seek to promote organic and regenerative farming.

Contradicting what the discussion on Gillams webcast suggested, exposure to glyphosate traces in our urine is not unusual almost any common toxic chemical shows up in parts per billion. As the chart below illustrates, Vitamin D is potentially hundreds of times more threatening. Glyphosate is less toxic than table salt. The caffeine in your morning cup of Joe is 22 times more toxic than the weedkillerbut like glyphosate, toxic caffeine is excreted from our bodies, harmlessly. Thank you, kidneys!

Since ancient times, it has been known that the dose makes the poison. Chemical risk comes down to how much we are exposed to and how long. And as Dr. Kabat reported in his article, the state-of-the art National Cancer Institutes Agricultural Health Study, which tracked farm workers exposed to glyphosate over decades, showed no association of glyphosate with any of more than twenty types of cancer.

So, despite the noise created by Gillam and activist groups, no reputable oversight or assessment agency in the worldnot oneconsiders trace levels of glyphosate as noted in our urine at the levels cited by the CDC as potentially harmful.

A recent similar urine analysis report, drawing on the same CDC database, on another herbicide conducted by a group called the Heartland Study was exposed in this article by Cornell microbiologist Dr. Kathleen Hefferon. It had similar methodological flaws and serious academic ethical breaches. The analysis was led by glyphosate litigation consultant Charles Benbrook [Read GLP profile of Benbrook]. Benbrook, an economist with no formal background in toxicology, is known in legal circles as an anti-chemical consultant for hire when organic clients want removed from the market).

The CDC report would have been a footnote in a mountain of mostly useless data until it was weaponized by Carey Gillam.Besides her skewed analysis that ran in The Guardian, she placed it at her partner organizations accompanied: on EWGs site (which exaggerated the data, claiming CDC found 87%); and on vaccine denier Robert F. Kennedys Childrens Health Defense e-mag, The Defender, for which Gillam writes regularly and has a dedicated column page. (The Defender is committed to defending children from getting life-saving routine vaccines, including COVID vaccines.)

Carey Gillam has been the most visible and relentless critic of agricultural chemicals for a decade. What is her background? What follows is a more accurate primer on her background.[Read GLP backgrounder of one of Gillams books here]

Gillam has a history as a longtime Monsanto antagonist and critic of conventional agriculture. She was affiliated with Reuters for 17 years, much of it covering food and farming in the Midwest. According to Freedom of Information documents, she left under a cloud after being confronted by her editor in 2015, after years of complaints from independent scientists about her lack of editorial balance and her embrace of anti-GMO conspiracy propaganda. Her anti-GMO activist friends were well aware that editors at Reuters had challenged her for apparently compromising journalistic standards and ethics.

When contacted by the GLP, Gillam denied being forced out under pressure from Reuters management, claiming she has paperwork to support her claim, but she refused to share it.Shortly after leaving Reuters, Gillam was named research director at US Right to Know, where the constraints of objective journalism that she reportedly challenged were no longer in place.

Tomorrow, we will examine Carey Gillams work as a frontperson for the anti-GMO industry and the web of pro-organic corporations and activist groups that profit from her advocacy.

Jon Entineis the foundingexecutivedirectorof theGenetic Literacy Project, and winner of 19 major journalism awards. He has written extensively in the popular and academic press on media ethics, corporate social responsibility, sustainability, and agricultural and population genetics. You can follow him on Twitter@JonEntine.The GLP discloses all major contributors and conflicts of interest, and outlines its donor policy on itstransparency page.

Continue reading here:
Part 1: Carey Gillam Reporter turned organic propagandist who twists science in her campaign to discredit biotechnology and conventional agriculture...

Key CompaniesCovered in theBlue Biotechnology MarketResearch areAker Biomarine, Cellgen Biologicals Pvt Ltd., Donald Danforth Plant Science Center, Geomarine Biotechnologies, Glycomar, Marinova, Nurture Aqua Technology Pvt., New England Biolabs, Pices, Pml Application Ltd., Sea Run Holdings, Inc., Shell Marine Products, Sanosil Biotech, and Samudra Biopharma Private Limited.and other key market players.

The report covers the analysis and forecast of the blue biotechnology market on global as well as regional level. The study provides historic data of 2016 along with the forecast for the period between 2017 and 2025 based on revenue (US$ Mn).

Download Free Sample of This Strategic Report:https://reportocean.com/industry-verticals/sample-request?report_id=5444

The study provides a detailed view of the blue biotechnology market, by segmenting it based on by product type, by application, by end- user and regional demand. Robust growth of drug discovery in the past several years propels the growth for the blue biotechnologys market. Growing usage of algae along with other bacteria for producing a new drug is another prime factor driving the market demand. Additionally, extensive use of blue biotechnologys in end-user industries such as pharmaceutical, research organization, healthcare, and others boosts the demand of this market.

Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Middle East and Africa and Latin America. The segmentation also includes by product type, by application and end- user in all regions. These include different business strategies adopted by the leading players and their recent developments.

A comprehensive analysis of the market dynamics that is inclusive of market drivers, restraints, and opportunities is part of the report. Additionally, the report includes potential opportunities in the blue biotechnology market at the global and regional levels. Market dynamics are the factors which impact the market growth, so their analysis helps understand the ongoing trends of the global market. Therefore, the report provides the forecast of the global market for the period from 2017 to 2025, along with offering an inclusive study of the blue biotechnology market.

Request To Download Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sample-request?report_id=5444

The report provides the size of the blue biotechnology market in 2017 and the forecast for the next eight years up to 2025. The size of the global blue biotechnology market is provided in terms of revenue. Market revenue is defined in US$ Mn. The market dynamics prevalent in North America, Europe, Asia Pacific, Middle East and Africa and Latin America has been taken into account in estimating the growth of the global market.

Market estimates for this study have been based on revenue being derived through regional pricing trends. The blue biotechnology market has been analyzed based on expected demand. Bottom-up approach is done to estimate the global revenue of the blue biotechnology market, split into regions. Based on product type, application, and end- user, the individual revenues from all the regions is summed up to achieve the global revenue for blue biotechnology. Companies were considered for the market share analysis, based on their innovation, end- user and revenue generation. In the absence of specific data related to the sales of blue biotechnology several privately held companies, calculated assumptions have been made in view of the companys penetration and regional presence.

The global blue biotechnology market has been segmented into:

Global Blue Biotechnology Market: By Product Type Pharma Biofuels Food Enzymes Biopolymers Others

Global Blue Biotechnology Market: By Application Vaccine development Drug finding Genomics Others

SPECIAL OFFER (Avail an Up-to 30% discount on this report-https://reportocean.com/industry-verticals/sample-request?report_id=5444

Global Blue Biotechnology Market: By End- User Pharmaceutical companies Biotechnology companies Research organization Healthcare centre Others

Global Blue Biotechnology Market: By Geography North Americao U.S.o Canadao Mexico Europeo U.K.o Franceo Germanyo Italyo Rest of Europe Asia Pacifico Indiao Chinao Japano Rest of Asia Pacific Middle East and Africao South Africao Rest of Middle East and Africa Latin Americao Brazilo Rest of Latin America

Table of Content:

Key Questions Answered in the Market Report

Request full Report:https://reportocean.com/industry-verticals/sample-request?report_id=5444

About Report Ocean:We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:Report Ocean:Email:sales@reportocean.comAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATESTel:+1 888 212 3539 (US TOLL FREE)Website:https://www.reportocean.com

Link:
Blue Biotechnology Market Outlook by Industry Revenue, Regions and Top Key Players 2022-2030 This Is Ardee - This Is Ardee

BOSTON, July 26, 2022 /PRNewswire/ --STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics for rare blood diseases, announced today it has been awarded a Small Business Innovation Research (SBIR) grant for approximately $2,100,000 from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). The award will allow the company to further advance its proprietary EV technology for use as a novel non-viral gene therapy delivery platform.

The specific objective of this NIH funding opportunity is to support the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with the goal of enabling the use of genome editing therapeutics to treat human disease. STRM.BIO has developed a proprietary, large capacity EV-based system for in vivo nucleic acid and protein delivery that specifically targets hematopoietic stem cells (HSCs) in bone marrow, is amenable to large scale commercial manufacture, and presents with low immunogenicity which confers unique potential for repeat dosing.

"It is critical to the future of the field that the next generation of gene therapies be delivered as simple injections in standard clinical settings," said Jonathan Thon, CEO and Founder of STRM.BIO. "Current ex vivo approaches, in which a patient's cells are edited in culture and then transplanted, are not a sustainable model. Patients undergo harsh conditioning before receiving an ex vivo gene therapy treatment, which often has severe side effects and can be fatal. These treatments also require specialized facilities and training and are too expensive to be supported by payers as a routine option. Our EV-based delivery system has the potential to efficiently deliver gene editors safely to the bone marrow following intravenous injectionspecifically the long-term HSCs in the bone marrow we all strive to target for durable gene correction. This is big. This precision targeting creates promising new options to treat rare blood diseases and represents a paradigm shift over HSC transplant."

This SBIR award will enable the company to optimize procedures for loading their proprietary EVs with cargo, further characterize the biodistribution and delivery pattern of cargo-loaded EVs, and verify feasibility of STRM.BIO EVs for in vivo cargo delivery in a pre-clinical model of human genetic hematologic disease. With this grant, the company aims to expand pre-clinical proof-of-concept support for the use of this novel system as a non-viral, in vivo genome editor delivery system for the treatment of inherited hematologic diseases.

About STRM.BIO

Based in Boston, MA, STRM.BIO is a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapy in a better way: simpler, safer, practical. Our work will open the door to the future of medicine for patients living with rare diseases worldwide. STRM.BIO is committed to bringing gene therapy to life. Please visit strm.bioand follow us on Twitter @STRMbio and on LinkedInto meet our growing team of partners and collaborators and stay up to date on our progress.

SOURCE STRM.BIO

Read more:
STRM.BIO Receives $2.1 Million SBIR Grant to Advance Extracellular Vesicle Technology for Non-Viral, In Vivo Delivery of Gene Therapies - PR Newswire

There is no area of human activity more basic to society than a sustainable agricultural, food, and natural resource system. With projections that global population will grow to as much as 10 billion by 2050 (Pew Research Center 2022), there is increasing concern as to how this system should be transformed to feed this population sustainably.

Serious questions need to be addressed; for example: What will constitute a healthy diet? Will natural resources and ecosystems be compromisedor even destroyedin efforts to provide such a diet? Will the food system reduce or increase hunger and poverty? And will the system enhance or decrease equity and access to food for a healthy and productive global population? These and other critical questions challenge all who participate in the food and agriculture system (FAS), and more broadly everyone is involved at some level, from daily consumption to innovative scientific research.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

An article by the CROPPS Research Community emphasizes the need for a deeper understanding of the biology of plants and their responses to a changing climate, among other factors. The vision and work of the Center for Research on Programmable Plant Systems (CROPPS) focus on understanding the deep biology of plants to create an Internet of Living Things. The vision depends on transdisciplinary collaborationbiotechnology and synthetic biology, robotics and automation, sensing and automation, and computingto enable a digital dialogue with plant systems.

This is an excerpt. Read the original post here

Follow this link:
How biotechnology will transform the food and agriculture system - Genetic Literacy Project

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. ( SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D. will become an executive director at the prestigious University of Colorado Gates Institute. Dr. Fry, a world-renowned expert in chimeric antigen receptor T cell (CAR T) therapies, has devoted part of his time to the University of Colorado as a clinical professor of pediatric oncology since joining Sana. He continues to work in his current Sana role without change while serving as the Institutes Executive Director.

Terry is a leader in the cell and gene therapy space, particularly in developing CAR T therapies for cancer patients. We are proud of Terry and his appointment at the University of Colorado Gates Institute, as his close collaboration with academia will continue to be extremely valuable to the field and to Sana as we explore diverse scientific tools to modify genes and use cells as medicines to change the outcome of many human diseases, said Steve Harr, Sanas President and Chief Executive Officer. Terrys appointment further underscores the high caliber of talent that we have throughout the Sana organization and adds to the number of our team leading institutes in top academic centers.

Dr. Fry added, Bringing innovative therapies to patients remains my first priority, and I am optimistic about the pipeline we are progressing at Sana. My continued involvement in the academic arena fuels greater understanding into novel territories in gene and cell therapy with the goal of bridging and leveraging new insights across industry and academia to propel the field forward.

Yesterday, the University of Colorado announced the creation of the Gates Institute, a state-of-the-art facility that will focus on rapidly translating laboratory findings into regenerative, cellular, and gene therapies for patients. Working in partnership with CU Anschutz, the Gates Institute, fueled by a philanthropic investment from the Gates Frontiers Fund, and an investment by CU Anschutz, is expected to grow to $200 million over the next five years. The institute will build on the success of the Gates Center for Regenerative Medicine and Gates Biomanufacturing Facility, which have conducted groundbreaking stem cell research for cancer and rare diseases, pioneering new therapies in recent years. Dr. Fry will become its Executive Director.

About Sana

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the Company, we, us, or our) within the meaning of the federal securities laws, including those related to the companys vision, progress, and business plans, the scope of Dr. Frys employment with Sana, and the potential value to the Company of Dr. Frys collaboration with academia. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Companys strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as aim, anticipate, assume, believe, contemplate, continue, could, design, due, estimate, expect, goal, intend, may, objective, plan, positioned, potential, predict, seek, should, target, will, would and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Companys current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Companys actual results, please refer to the risk factors identified in the Companys SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated May 10, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:Nicole Keith[emailprotected][emailprotected]

Go here to see the original:
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, MD, on Additional Role at the University of...

Tiziana Life Sciences Plc

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via novel routes of administration today announced that its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will present at the Biotechnology Innovation Organization (BIO) Annual Convention taking place at the San Diego Convention Center, Monday June 13 - Thursday, June 16, 2022. His presentation will be primarily focused on the recent clinical updates on nasal administration of foralumab, a fully human anti-CD3 monoclonal antibody, for treatment of patients with secondary progressive multiple sclerosis. He will also provide an update on the initiation of Phase 1b trial with first-ever oral capsules of foralumab for treatment of patients with mild-to-moderately active Crohns Disease. Company management will also be participating in one-on-one meetings throughout the conference.

Presentation Information

Presenter: Kunwar Shailubhai, Ph.D., Chief Executive Officer and Chief Scientific Officer, Tiziana Life SciencesTitle: Enabling Breakthrough Immunotherapies via Novel Routes of Drug Delivery

Day: Tuesday, June 14thTime: 2:00- 2:15 pm PDTLocation: Theater 1

To register for the conference and schedule a one-on-one meeting with Tiziana Life Sciences management, please visit https://www.bio.org/events/bio-international-convention/registration.

Dr. Shailubhai will also attend the BioNJ 29th Annual Dinner Meeting and Innovation Celebration, gathering and honoring members of New Jerseys life science ecosystem, on Thursday, June 9, 2022 at 4:45 pm EDT. This meeting, taking place at the Hilton in East Brunswick New Jersey, was originally planned for February, and was postponed due to the surge of the Omicron variant.

About BIO and the BIO International ConventionThe Biotechnology Innovation Organization (BIO) is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. Our mission is to be the champion of biotechnology and the advocate for our member organizationsboth large and small. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. We also represent state and regional biotech associations, service providers to the industry and academic centers. Currently there are over 3,000+ international and domestic companies registered to attend BIO 2022 across the biotech industry.

Story continues

About BioNJFounded in 1994, BioNJ, the New Jersey partner of BIO, has been hard at work in its mission to enhance the climate for life sciences in the State. As the representative of an industry that has the potential to change the course of human health, make our environment cleaner and the foods we eat safer and healthier, BioNJ is single-minded in its commitment to the growth and prosperity of this industry within the state of New Jersey.

About Tiziana Life SciencesTiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tizianas innovative intranasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tizianas two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tizianas technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further information please contact:

Tiziana Life Sciences:Hana Malik, Business Development and Investor Relations Manager +44 (0) 207 495 2379email:info@tizianalifesciences.com

United States:

Investors:Irina KofflerLifeSci AdvisorsTel: (646) 970-4681ikoffler@lifesciadvisors.com

Read more:
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical...

Real Life Global Humanitarian Affairs Foundation has urged the federal government to utilise biotechnology for increased yields through genetic modified seeds and prevent importation of food products.

According to Daily Trust report, Engr Akinsola Akinsoji, the National Coordinator of Real Life, stated that the increased rate of insecurity had deterred farmers from accessing their farmlands, but that biotech could help to secure food security in the country.

Akinsoji added that with South Africa earning over $600m from genetic modified seeds in 20 years, it could be replicated in Nigeria and help widen the governments revenue.

Also Read: Free Trade Zones Contributes N29bn Tax In 2 Years NEZA

He said, For some reasons we are yet to adopt technology in our farms even as modernised farming is yet to kick-start in large scale, but without the adoption of technology, we will not be able to feed Nigerians. We all know what happened when the border was shut against rice.

He further said the use of the modified cowpea seed in the country was slow due to opposition by producers of pesticides, but pointed out that larger economic value would increase revenue base if farmers and government adopted biotech.

On whether farmers can afford it, he stated that the seeds were readily available to the farmers and that they didnt have to spend much money on it.

The government has already established the National Biotechnology Development Agency (NABDA) and they are working assiduously to make sure that the technology is made simple for every Nigerian. Our work is to break it down to the people. Farmers do not have the economic power and understanding, so we get training from the agencies and take it to them in their local languages.

Source: Daily Trust

Related

Excerpt from:
FG Urged to Adopt Biotechnology in Agriculture to Save Economy - Economic Confidential